of CNS disorders
neurons to fight neurodegenerative diseases.
Areas of Focus
Alzheimer’s disease is characterized by an age-related buildup of toxic proteins in the brain, which bind to receptors and disrupt key cellular processes. CT1812, Cognition Therapeutics’ lead product candidate, has been shown to displace toxic protein oligomers that have attached to neurons, potentially restoring normal cellular function.
Watch our mechanism of action video to learn more.
Age-related buildup of toxic proteins is also known to be a cause of dementia with Lewy bodies (DLB), the second most common form of degenerative dementia. CT1812 is believed to help maintain the function of the sigma-2 receptor and has the potential to protect neurons from the two types of pathogenic proteins known to drive the progression of DLB.